Aptabio Therapeutics Inc. has identified new pyrazole derivatives acting as reactive oxygen species (ROS) production inhibitors reported to be useful for the treatment of cancer, neurodegeneration, fibrosis, liver diseases and dermatological, eye and inflammatory disorders, among other disorders.

Oncolinx Pharmaceuticals LLC and the U.S. Department of Health and Human Services have presented new signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, and bacterial and viral infections.

Blossomhill Therapeutics Inc. has divulged macrocyclic compounds acting as epidermal growth factor receptor (EGFR: HER1; erbB1) and EGFR mutant inhibitors reported to be useful for the treatment of cancer.

Researchers from Sun Yat-sen University, Southern Medical University and Gannan Medical University reported the discovery of novel quinazoline-based KRAS G12C inhibitors as potential anticancer agents.

Tsd Life Sciences Co. Ltd. has discovered imidazopyridine derivatives acting as protein kinase inhibitors and reported to be useful for the treatment of cancer.

Korea University Research and Business Foundation (KURBF) has identified adamantyl derivatives acting as dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, Parkinson's disease, nonalcoholic steatohepatitis (NASH), rheumatoid arthritis, aortic valve stenosis and cerebrovascular and dermatological disorders.

Netris Pharma SAS has entered into a scientific collaboration agreement with Orano SA and the Centre Léon Bérard (CLB) to develop novel antibody-radio conjugates for the treatment of cancer.